These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31864154)

  • 1. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.
    Dou F; Zhang Y; Yi J; Zhu M; Zhang S; Zhang D; Zhang Y
    Thromb Res; 2020 Feb; 186():36-41. PubMed ID: 31864154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
    Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
    Lee YG; Kim I; Lee E; Bang SM; Kang CH; Kim YT; Kim HJ; Wu HG; Kim YW; Kim TM; Lee KW; Lee SH; Kim DW; Heo DS
    Thromb Haemost; 2014 Jun; 111(6):1112-20. PubMed ID: 24477503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.
    Dou F; Li H; Zhu M; Liang L; Zhang Y; Yi J; Zhang Y
    Respir Res; 2018 May; 19(1):88. PubMed ID: 29743116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC.
    Al-Samkari H; Leiva O; Dagogo-Jack I; Shaw A; Lennerz J; Iafrate AJ; Bendapudi PK; Connors JM
    J Thorac Oncol; 2020 Sep; 15(9):1497-1506. PubMed ID: 32437899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
    Roopkumar J; Poudel SK; Gervaso L; Reddy CA; Velcheti V; Pennell NA; McCrae KR; Khorana AA
    J Thromb Haemost; 2021 Mar; 19(3):822-829. PubMed ID: 33314597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
    Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
    J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
    Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
    Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis.
    Abufarhaneh M; Pandya RK; Alkhaja A; Iansavichene A; Welch S; Lazo-Langner A
    Thromb Res; 2022 May; 213():47-56. PubMed ID: 35290837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
    J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
    Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
    Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma.
    Yang S; Yang L; Wu Y; Zhang C; Wang S; Ma N; Wang L; Wang Q
    Ann Transl Med; 2020 Oct; 8(20):1307. PubMed ID: 33209887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
    Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR
    Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.